{
    "nct_id": "NCT04838626",
    "official_title": "Phase II/III Study for Evaluation of the Diagnostic Performance of [18F]CTT1057 PET Imaging for the Detection of PSMA Positive Tumors Using Histopathology as a Standard of Truth",
    "inclusion_criteria": "* Untreated high risk biopsy-proven PCa patients according to D'Amico classification (Stage ≥ T2c or PSA level >20ng/ml or Gleason score ≥8) (D'Amico et al 1998)\n* Scheduled or planned radical prostatectomy and extended pelvic lymph node resection up to 6 weeks after the investigational PET/CT scan followed by histopathology assessment\n* ECOG performance status 0-2\n* Signed informed consent must be obtained prior to participation in the study\n* Participants must be adults ≥ 18 years of age\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Inability to complete the needed investigational and standard-of-care imaging examinations due to any reason (severe claustrophobia, inability to lie still for the entire imaging time, etc.)\n* Any additional medical condition, serious intercurrent illness, concomitant cancer or other extenuating circumstance that, in the opinion of the Investigator, would indicate a significant risk to safety or impair study participation, including, but not limited to, current severe urinary incontinence, hydronephrosis, severe voiding dysfunction, need of indwelling/condom catheters, New York Heart Association class III or IV congestive heart failure, history of congenital prolonged QT syndrome, uncontrolled infection, active hepatitis B or C, and COVID-19.\n* Known allergy, hypersensitivity, or intolerance to [18F]CTT1057\n* Prior and current use of PSMA targeted therapies\n* Prior and current treatment with any ADT (first or second generation), including LHRH analogues (agonists or antagonists)\n* Any 5-alpha reductase inhibitors within 30 days before screening\n* Patients with small cell or neuroendocrine PCa in more than 50% of biopsy tissue\n* Patients with incidental PCa after transurethral resection\n* Use of other investigational drugs within 30 days before screening",
    "miscellaneous_criteria": ""
}